Poisoning Related to Ivermectin Exposure for COVID-19 Described
Twenty-one cases of poisoning for ivermectin exposure relating to COVID-19 were reported to the Oregon Poison Center in August 2021.
Related Articles
Monoclonal Antibodies in Eosinophilic COPD Safely Reduce Exacerbations
Treating eosinophilic COPD with monoclonal antibodies significantly reduces exacerbations vs standard care, with an acceptable safety profile.
Ensifentrine Is a Promising Ancillary COPD Treatment Option
Ensifentrine is a promising supplementary therapeutic option in the management of COPD.
Does Short-Term Heart Rate Variability Predict Impaired Vigilance in OSA?
Short-term HRV is significantly associated with poor daytime psychomotor vigilance performance among both men and women with OSA.
Spirometry: PRISm Linked to Higher Mortality Risk
Preserved ratio impaired spirometry (PRISm) is associated with an increased mortality risk.
Malpractice: Why Pulmonologist Lost Dismissal Motion Challenging Expert Testimony
Pulmonologist sued for medical malpractice sought to have the case dismissed on the grounds that testimony supporting the case’s validity was insufficient.
In Rural Appalachia, Pulmonologist Treats Coal Miners Affected by Black Lung Disease
The incidence of so-called “black lung disease” has been roaring back due to mechanized coal extraction technology.
Phaware Founder Devotes His Life to PH Advocacy After Losing His Son to the Disease
Steve Van Wormer has published nearly 500 podcasts about pulmonary hypertension (PH) — more than perhaps anyone working in rare diseases.
Cannabis Dabbing, Which Has High THC Levels, Linked to Lung Impairments
Cannabis dabbing, an increasingly popular way to consume highly concentrated THC, has been linked to pulmonary and neurologic impairments.
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
2024 Novel Drug and Biological Product Approvals
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.